Scinai details grant for CDMO expansion in 6-K

Scinai Immunotherapeutics Ltd. filed a Form 6-K describing a new grant award from the Israel Innovation Authority.

Rhea-AI Filing Summary

Scinai Immunotherapeutics Ltd. filed a Form 6-K describing a new grant award from the Israel Innovation Authority. The grant is intended to support expansion of the company’s fill-and-finish capabilities as a contract development and manufacturing organization (CDMO), which are services used by biopharma companies to prepare and package biological products.

The company reports that it issued a press release about this grant on October 6, 2025, which is attached as an exhibit to the filing. Scinai also states that this Form 6-K, with limited exceptions, is incorporated by reference into its existing registration statements on Form S-8 and Form F-3, meaning the disclosed information becomes part of those previously filed securities registration documents.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Scinai Immunotherapeutics (SCNI) report in this Form 6-K?

Scinai Immunotherapeutics reported that it received an award from the Israel Innovation Authority Grant to expand its fill-and-finish CDMO capabilities and furnished a related press release as an exhibit.

What is the purpose of the Israel Innovation Authority grant mentioned by Scinai (SCNI)?

The grant is described as supporting Scinai Immunotherapeutics in expanding its fill-and-finish contract development and manufacturing organization (CDMO) capabilities, which relate to preparing and packaging biopharmaceutical products.

Which exhibits are included with this Scinai Immunotherapeutics Form 6-K?

The filing includes one exhibit, labeled 99.1, which is a press release dated October 6, 2025 describing the Israel Innovation Authority grant and expansion of CDMO capabilities.

How does this Form 6-K affect Scinai Immunotherapeutics’ existing registration statements?

Scinai states that this Form 6-K, other than a specified paragraph in the press release, is incorporated by reference into its registration statements on Form S-8 and Form F-3, making this information part of those securities registration documents.

Who signed the Scinai Immunotherapeutics (SCNI) Form 6-K?

The Form 6-K was signed on behalf of Scinai Immunotherapeutics Ltd. by Amir Reichman, who is identified as the company’s Chief Executive Officer.

Does the Scinai (SCNI) Form 6-K disclose financial results or earnings data?

This Form 6-K focuses on the Israel Innovation Authority grant and incorporation by reference into registration statements; it does not present financial statements or earnings data in the provided excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/06/2025 - 07:45 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of October 2025

Commission File Number: 001-37353

SCINAI IMMUNOTHERAPEUTICS LTD.

(Translation of registrant’s name into English)

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

Jerusalem, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

EXPLANATORY NOTE 

On October 6, 2025, Scinai Immunotherapeutics Ltd. issued a press release announcing an award by the Israel Innovation Authority Grant to expand fill-and-finish CDMO capabilities.

A copy of the press release is furnished herewith as Exhibit 99.1.

This Report on Form 6-K (other than the paragraph immediately preceding the headline “Serving Early-Stage Biotech Clients Worldwide”) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344) and Form F-3 (File No. 333-274078 and File No. 333-276767), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit Index

Exhibit No.		Description
99.1		Press release dated October 6, 2025.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Scinai Immunotherapeutics Ltd.
Date: October 6, 2025	By:	/s/ Amir Reichman
		Amir Reichman
		Chief Executive Officer

2